ARBUTUS BIOPHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.73 USD | +0.37% |
|
+0.37% | +9.20% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
| Sales 2024 * | 12.63M 9.23M | Sales 2025 * | 13.59M 9.94M | Capitalization | 671M 491M |
|---|---|---|---|---|---|
| Net income 2024 * | -113M -82.6M | Net income 2025 * | -130M -95.03M | EV / Sales 2024 * | 53.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 49.4 x |
| P/E ratio 2024 * |
-6.16
x | P/E ratio 2025 * |
-5.18
x | Employees | 73 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arbutus Biopharma Corporation
More recommendations
More press releases
| 1 day | +0.37% | ||
| 1 week | +0.37% | ||
| Current month | +5.81% | ||
| 1 month | +9.64% | ||
| 3 months | +14.71% | ||
| 6 months | +55.11% | ||
| Current year | +9.20% |
1 week
2.64
2.78
1 month
2.303.29
Current year
2.213.29
1 year
1.693.29
3 years
1.696.50
5 years
0.829.02
10 years
0.8229.93
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 58 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.73 | +0.37% | 405,768 |
| 24-04-25 | 2.72 | -1.09% | 323,341 |
| 24-04-24 | 2.75 | 0.00% | 348,057 |
| 24-04-23 | 2.75 | +4.17% | 1,089,465 |
| 24-04-22 | 2.64 | -2.94% | 740,415 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.726
CAD
Average target price
5.962
CAD
Spread / Average Target
+60.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.20% | 490M | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- ABUS Stock
